Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $210

Benzinga Newsdesk www.benzinga.com Positive 87.3%

Neg 0% Neu 0% Pos 87.3%

Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $207 to $210.